论文部分内容阅读
目的:探讨乳腺癌患者HER4与HER2、ER、PR之间的关系及其对乳腺癌预后的影响。方法:采用免疫组化SP法检测105例乳腺癌组织中HER4、HER2、ER、PR蛋白的表达。对患者随访,随访终点为无病生存时间(disease free survival,DFS)。结果:HER2、HER4、ER、PR在105例乳腺癌患者中的阳性表达率分别为:37.14%、20.00%、40.00%、28.27%;HER4与年龄、淋巴结转移、分期、肿瘤类型以及是否化疗的差异性均无统计学意义(P﹥0.05);HER4可刺激ER、PR产生(P=0.030,P=0.028);HER4阳性与阴性患者无病生存时间差异有统计学意义(P=0.039);HER4(+)HER2(-)组乳腺癌患者较其他组无病生存时间明显延长(P=0.000)。结论:HER4可作为独立的临床预后因子,HER4可延长乳腺癌患者无病生存时间并可刺激ER、PR的产生。
Objective: To investigate the relationship between HER4, HER2, ER and PR in patients with breast cancer and its effect on the prognosis of breast cancer. Methods: Immunohistochemical SP method was used to detect the expression of HER4, HER2, ER and PR in 105 cases of breast cancer. The patients were followed up for the end of follow-up for disease free survival (DFS). Results: The positive rates of HER2, HER4, ER and PR in 105 cases of breast cancer were 37.14%, 20.00%, 40.00% and 28.27% respectively. The positive rates of HER4, age, lymph node metastasis, staging, tumor type and chemotherapy (P = 0.030, P = 0.028). There was significant difference in the disease-free survival time between HER4 positive and negative patients (P = 0.039). There was no significant difference between the HER4 positive and negative patients (P> 0.05) Patients with HER4 (+) HER2 (-) breast cancer had significantly longer disease-free survival than the other groups (P = 0.000). Conclusion: HER4 can be an independent clinical prognostic factor. HER4 can prolong the disease-free survival time of breast cancer patients and stimulate the production of ER and PR.